Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs.
Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J; Adult AIDS Clinical Trials Group A5221 Study Team. Luetkemeyer AF, et al. Among authors: benson ca. J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):423-8. doi: 10.1097/QAI.0000000000000030. J Acquir Immune Defic Syndr. 2014. PMID: 24226057 Free PMC article. Clinical Trial.
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.
Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS; International AIDS Society-USA. Schambelan M, et al. Among authors: benson ca. J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75. doi: 10.1097/00126334-200211010-00001. J Acquir Immune Defic Syndr. 2002. PMID: 12439201 Review.
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW; ACTG A5086 Study Team. Benson CA, et al. J Infect Dis. 2006 Nov 1;194(9):1309-18. doi: 10.1086/508289. Epub 2006 Sep 22. J Infect Dis. 2006. PMID: 17041858 Clinical Trial.
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.
Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu R; ACTG-ALLRT Protocol Team. Krishnan S, et al. Among authors: benson ca. Oncology. 2011;80(1-2):42-9. doi: 10.1159/000328032. Epub 2011 May 23. Oncology. 2011. PMID: 21606663 Free PMC article.
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F; Adult AIDS Clinical Trials Group A5221 Study Team. Luetkemeyer AF, et al. Among authors: benson ca. Clin Infect Dis. 2013 Aug;57(4):586-93. doi: 10.1093/cid/cit246. Epub 2013 Apr 16. Clin Infect Dis. 2013. PMID: 23592830 Free PMC article.
TB-IRIS after initiation of antiretroviral therapy is associated with expansion of preexistent Th1 responses against Mycobacterium tuberculosis antigens.
Vignesh R, Kumarasamy N, Lim A, Solomon S, Murugavel KG, Balakrishnan P, Solomon SS, Mayer KH, Swathirajan CR, Chandrasekaran E, Pradeep A, Poongulali S, Benson CA, French MA. Vignesh R, et al. Among authors: benson ca. J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):241-8. doi: 10.1097/QAI.0b013e31829f6df2. J Acquir Immune Defic Syndr. 2013. PMID: 23774879 Free PMC article.
231 results